

DSHS Pharmacy Spend and Utilization

Prescription Drug Price and Purchasing Summit
–Part 1

Katy Tomisser
June 14, 2016

Total Drug Spend CY 2015

Western State Hospital (WSH):

\$3,958,857

Eastern State Hospital (ESH):

\$2,226,487

Developmental Disabilities Administration (DAA)
Institutions:

\$4,391,613

Total:

\$10,576,957

Top 5 Drugs by Cost

Western State Hospital	Eastern State Hospital	Developmental Disabilities
Risperdal Consta®	Invega Sustenna®	Prolia®
Aripiprazole (Abilify®)	Risperdal Consta®	Vimpat®
Clozapine (Clozaril®)	Latuda®	Aripiprazole (Abilify®)
Olanzapine (Zyprexa®)	Aripiprazole (Abilify®)	Invega®
Chlorpromazine	Invega®	Sodium phenylbutyrate

Top 5 Drugs by Utilization for WSH

Western State Hospital	Eastern State Hospital	Developmental Disabilities
Olanzapine	Polyethylene Glycol	Polyethylene Glycol
Divalproex	Lactulose	Lactulose
Docusate	Olanzapine inj	Acetaminophen
Polyethylene Glycol	Senna/Docusate	Acidophilus
Lithium		Levocarnitine

Management Strategies

- ▶ Behavioral Health Administration (BHA) joint formulary between WSH/ESH
- ▶ DDA pharmacy formulary and quarterly P&T meetings
- ▶ WSH, ESH, & DDA joining Group Purchasing Organization (GPO) Premier Contract through PeaceHealth/CCG to improve purchasing power
- ▶ Trying to restrict long-acting injectable antipsychotics to patients within 4 months of expected discharge
- ▶ DDA purchasing technician and Medicare Program Specialist to evaluate pricing trends and market shifts

Barriers and Challenges

Provider Demands

Drugs restricted through DSHS but covered by Medicaid

Patients refusing to take oral medications and requiring more expensive injectable medications

Generic drug manufacturer consolidation

- Chlorpromazine rose 4000% in 3 years
- Was \$20-\$30 per bottle, now \$800-\$1,000

Brand manufacturers entering into exclusivity agreements with Medicare Part D plans to maintain brand drugs on formulary when less costly alternative generics are available.